AstraZeneca extends cancer care partnership, shares backed by a clear London consensus

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 16:17.

AstraZeneca (GB0009895292) highlights a new US partnership with YMCA of the USA to address gaps in cancer care and survivorship, while its primary listing on the London Stock Exchange continues to attract analyst support. The partnership focuses on community-based cancer screening and support programs in the US, adding a public health dimension to the FTSE 100 constituent’s oncology franchise.

What the partnership adds

The partnership between AstraZeneca and YMCA of the USA was announced in late June 2026 and is framed as a "landmark" initiative aimed at addressing inequalities in cancer care, including access to screening and survivorship services. According to coverage compiled by MarketScreener and specialist health media, the program is designed to link local YMCA centers with evidence-based screening pathways and support services for patients and families.

AstraZeneca positions the initiative within its broader oncology strategy, where community outreach is meant to complement its portfolio of targeted therapies and immuno-oncology drugs. The company has in recent years emphasized earlier diagnosis and better patient navigation as cost-effective ways to improve outcomes alongside the introduction of new medicines.

Analyst consensus on London shares

On the London Stock Exchange, AstraZeneca shares trade under the ticker AZN with a current price around 13,966 pence, placing the market capitalization near £215.7 billion and a price/earnings ratio of about 27. Data from Investing.com UK shows a consensus "Buy" rating from 21 analysts, with 19 recommending Buy, 3 Hold and 1 Sell. The average 12-month price target stands around 16,760 pence, implying roughly 20 percent upside from the latest price level according to that survey.

The 52-week trading range for AstraZeneca shares spans from about 10,104 pence to 15,730 pence, which situates the current quotation in the upper half of that band. Hargreaves Lansdown data underline the company’s dividend profile, citing a most recent dividend of £1.595 per share, paid on 23 March 2026 after an ex-dividend date of 19 February 2026, translating into a yield near 1.7 percent at recent prices.

The business behind the stock

AstraZeneca generates most of its revenue from prescription medicines in oncology, cardiovascular, renal, metabolism and respiratory indications, with 2025 revenue reported around $58.7 billion and a global workforce of more than 96,000 employees. The company’s headquarters are located in Cambridge on the Cambridge Biomedical Campus, reinforcing its identity as a U.K.-based biopharmaceutical group with a strong research footprint.

Where the stock trades today

The AstraZeneca shares (GB0009895292) trade on the London Stock Exchange at around 13,966 pence on 2026-06-25, 14:00, according to recent London pricing data. That quotation reflects the company’s position as one of the larger healthcare constituents of the FTSE 100 index in the U.K. market.

This article is for informational purposes only and does not constitute investment advice, tax advice or a recommendation to buy or sell any financial instrument. All data are based on sources cited and may change over time.